FDA Inspection 1171848 — Hanlim Pharm Co. Ltd.

Hanlim Pharm Co. Ltd. — FEI 3004886113

The FDA completed an inspection of Hanlim Pharm Co. Ltd. on May 31, 2022 in Yongin. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 2 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
May 31, 2022
Fiscal Year
2022
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Yongin (Korea (the Republic of))

Citations

IDCFRDescription
125621 CFR 211.68(b)Backup file not maintained
127021 CFR 211.68(b)input/output verification